Clinical Trial Update: Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update assessing a COX-2 inhibitor for adjuvant anticancer effects in bile duct cancer and pancreatic cancer; current status is UNKNOWN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Pancreatic Cancer

Drugs mentioned

• Cyclooxygenase-2 inhibitor

Snippet

Sponsor: Seoul National University Hospital | Conditions: Bile Duct Cancer, Pancreatic Cancer | Phase 4 | Status: UNKNOWN